(ECL) Ecolab - Ratings and Ratios
Water Treatment, Hygiene Products, Infection Prevention, Pest Control
ECL EPS (Earnings per Share)
ECL Revenue
Description: ECL Ecolab September 26, 2025
Ecolab Inc. (NYSE:ECL) delivers water, hygiene, and infection-prevention solutions worldwide through four reportable segments: Global Industrial, Global Institutional & Specialty, Global Healthcare & Life Sciences, and Global Pest Elimination. The company’s product portfolio spans water-treatment chemicals, cleaning and sanitizing agents, and pest-control services, sold via field sales teams, corporate accounts, distributors, and dealers.
In FY 2023 Ecolab generated roughly $13.5 billion in revenue, with an adjusted operating margin of about 14 % and a free-cash-flow conversion rate near 70 %. The Global Industrial segment remains the largest revenue driver, benefiting from rising demand for water-recycling technologies in energy-intensive industries, while the Healthcare & Life Sciences segment is gaining traction as hospitals and pharma firms increase spending on infection-control protocols post-COVID-19.
Key macro-economic levers include global industrial production growth (especially in emerging markets), tightening environmental regulations that spur water-conservation investments, and inflationary pressure on raw-material costs, which can compress margins if not offset by pricing power. Ecolab’s historical ability to pass through cost increases and its focus on recurring service contracts provide a partial hedge against these risks.
For a deeper, data-driven look at Ecolab’s valuation scenarios and sensitivity analyses, the resources available on ValueRay may prove helpful.
ECL Stock Overview
| Market Cap in USD | 78,280m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | 1988-01-05 |
ECL Stock Ratings
| Growth Rating | 78.4% |
| Fundamental | 69.5% |
| Dividend Rating | 54.3% |
| Return 12m vs S&P 500 | -7.48% |
| Analyst Rating | 3.73 of 5 |
ECL Dividends
| Dividend Yield 12m | 0.94% |
| Yield on Cost 5y | 1.38% |
| Annual Growth 5y | 5.71% |
| Payout Consistency | 96.7% |
| Payout Ratio | 37.0% |
ECL Growth Ratios
| Growth Correlation 3m | 14.8% |
| Growth Correlation 12m | 80.6% |
| Growth Correlation 5y | 54.5% |
| CAGR 5y | 22.24% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.29 |
| CAGR/Mean DD 3y (Pain Ratio) | 6.17 |
| Sharpe Ratio 12m | 1.43 |
| Alpha | -10.36 |
| Beta | 1.096 |
| Volatility | 19.81% |
| Current Volume | 1516.6k |
| Average Volume 20d | 1425.6k |
| Stop Loss | 268.9 (-3%) |
| Signal | 0.07 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (2.14b TTM) > 0 and > 6% of Revenue (6% = 943.4m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -3.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.78% (prev 12.18%; Δ 1.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 2.62b > Net Income 2.14b (YES >=105%, WARN >=100%) |
| Net Debt (7.05b) to EBITDA (3.95b) ratio: 1.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (285.4m) change vs 12m ago -0.56% (target <= -2.0% for YES) |
| Gross Margin 43.97% (prev 42.60%; Δ 1.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.58% (prev 72.85%; Δ -3.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.60 (EBITDA TTM 3.95b / Interest Expense TTM 312.9m) >= 6 (WARN >= 3) |
Altman Z'' 3.91
| (A) 0.09 = (Total Current Assets 7.08b - Total Current Liabilities 4.91b) / Total Assets 23.74b |
| (B) 0.51 = Retained Earnings (Balance) 12.08b / Total Assets 23.74b |
| (C) 0.13 = EBIT TTM 3.00b / Avg Total Assets 22.60b |
| (D) 0.73 = Book Value of Equity 10.44b / Total Liabilities 14.39b |
| Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.51
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 1.84% = 0.92 |
| 3. FCF Margin 10.01% = 2.50 |
| 4. Debt/Equity 0.96 = 2.06 |
| 5. Debt/Ebitda 1.78 = 0.42 |
| 6. ROIC - WACC (= 5.38)% = 6.73 |
| 7. RoE 23.99% = 2.00 |
| 8. Rev. Trend 60.32% = 4.52 |
| 9. EPS Trend -12.83% = -0.64 |
What is the price of ECL shares?
Over the past week, the price has changed by -1.05%, over one month by +2.30%, over three months by +2.93% and over the past year by +9.20%.
Is Ecolab a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ECL is around 277.35 USD . This means that ECL is currently overvalued and has a potential downside of 0.04%.
Is ECL a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 13
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ECL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 288.3 | 4% |
| Analysts Target Price | 288.3 | 4% |
| ValueRay Target Price | 310.9 | 12.1% |
ECL Fundamental Data Overview October 25, 2025
P/E Trailing = 36.7674
P/E Forward = 32.2581
P/S = 4.9784
P/B = 8.3381
P/EG = 2.9303
Beta = 1.096
Revenue TTM = 15.72b USD
EBIT TTM = 3.00b USD
EBITDA TTM = 3.95b USD
Long Term Debt = 7.52b USD (from longTermDebt, last quarter)
Short Term Debt = 844.6m USD (from shortTermDebt, last quarter)
Debt = 8.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.05b USD (from netDebt column, last quarter)
Enterprise Value = 85.33b USD (78.28b + Debt 8.97b - CCE 1.92b)
Interest Coverage Ratio = 9.60 (Ebit TTM 3.00b / Interest Expense TTM 312.9m)
FCF Yield = 1.84% (FCF TTM 1.57b / Enterprise Value 85.33b)
FCF Margin = 10.01% (FCF TTM 1.57b / Revenue TTM 15.72b)
Net Margin = 13.59% (Net Income TTM 2.14b / Revenue TTM 15.72b)
Gross Margin = 43.97% ((Revenue TTM 15.72b - Cost of Revenue TTM 8.81b) / Revenue TTM)
Gross Margin QoQ = 44.78% (prev 44.32%)
Tobins Q-Ratio = 3.59 (Enterprise Value 85.33b / Total Assets 23.74b)
Interest Expense / Debt = 0.85% (Interest Expense 76.2m / Debt 8.97b)
Taxrate = 19.91% (131.4m / 659.9m)
NOPAT = 2.41b (EBIT 3.00b * (1 - 19.91%))
Current Ratio = 1.44 (Total Current Assets 7.08b / Total Current Liabilities 4.91b)
Debt / Equity = 0.96 (Debt 8.97b / totalStockholderEquity, last quarter 9.32b)
Debt / EBITDA = 1.78 (Net Debt 7.05b / EBITDA 3.95b)
Debt / FCF = 4.48 (Net Debt 7.05b / FCF TTM 1.57b)
Total Stockholder Equity = 8.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.00% (Net Income 2.14b / Total Assets 23.74b)
RoE = 23.99% (Net Income TTM 2.14b / Total Stockholder Equity 8.90b)
RoCE = 18.29% (EBIT 3.00b / Capital Employed (Equity 8.90b + L.T.Debt 7.52b))
RoIC = 14.47% (NOPAT 2.41b / Invested Capital 16.63b)
WACC = 9.09% (E(78.28b)/V(87.25b) * Re(10.05%) + D(8.97b)/V(87.25b) * Rd(0.85%) * (1-Tc(0.20)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 73.28% ; FCFE base≈1.77b ; Y1≈1.99b ; Y5≈2.67b
Fair Price DCF = 116.3 (DCF Value 32.97b / Shares Outstanding 283.6m; 5y FCF grow 14.34% → 3.0% )
EPS Correlation: -12.83 | EPS CAGR: -55.65% | SUE: -4.0 | # QB: 0
Revenue Correlation: 60.32 | Revenue CAGR: 3.42% | SUE: -0.33 | # QB: 0
Additional Sources for ECL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle